Company Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally.
The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands.
In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems.
The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE.
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
| Country | United States |
| Founded | 1849 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 88,000 |
| CEO | Dr. Albert Bourla D.V.M., Ph.D. |
Contact Details
Address: 66 Hudson Boulevard East New York, New York 10001-2192 United States | |
| Phone | (212) 733-2323 |
| Website | pfizer.com |
Stock Details
| Ticker Symbol | PFE |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000078003 |
| CUSIP Number | 717081103 |
| ISIN Number | US7170811035 |
| Employer ID | 13-5315170 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Albert Bourla D.V.M., Ph.D. | Chairman of the Board and Chief Executive Officer |
| David M. Denton | Chief Financial Officer and Executive Vice President |
| Dr. Mikael Dolsten M.D., Ph.D. | Chief Scientific Officer and President of Research and Development |
| Douglas M. Lankler | Executive Vice President and General Counsel |
| Aamir Malik | Executive Vice President and Chief U.S. Commercial Officer |
| Jennifer B. Damico | Senior Vice President, Controller and Principal Accounting Officer |
| Lidia L. Fonseca | Executive Vice President and Chief Digital and Technology Officer |
| Francesca M. DeMartino | Chief Investor Relations Officer |
| Rady A. Johnson | Executive Vice President and Chief Compliance, Quality and Risk Officer |
| Andreas J. Panayiotou | Global Chief Marketing Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Apr 11, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 28, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 28, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 14, 2024 | ARS | Filing |
| Mar 14, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 14, 2024 | DEF 14A | Other definitive proxy statements |